• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Journal Scan: The potential prognostic value of NT-proBNP assays in cats with congestive heart failure

July 20, 2017
Michael Nappier, DVM, DABVP

Comparing a cat's initial concentration of this assay with the results at discharge and during follow-up may help assess survival time.

Can serial NT-proBNP measurements give you a glimpse into a cat's future? (Shutterstock)Why they did it

Assays of N-terminal pro-B-type natriuretic peptide (NT-proBNP) has been used in veterinary medicine as single-point with a variety of applications in veterinary medicine. This includes helping in the diagnosis of subclinical and occult cardiac disease and differentiating cardiac and respiratory disease processes in cats. In people, changes in NT-proBNP concentrations during treatment for heart failure have been found to be indicative of long-term prognosis. The authors in this study sought to determine if the same applied to cats.

What they did

Thirty-one cats with congestive heart failure were enrolled and completed the study. Cats with hypertension, hyperthyroidism or renal failure were excluded. Within four hours of admission to the hospital, blood was drawn for a NT-proBNP concentration. Treatment for heart failure was initiated and further NT-proBNP concentrations were measured at time of discharge and at re-evaluation seven to 10 days after discharge. Owners were then contacted by phone every three months for an update until the cat died or was euthanized.

What they found

Advertisement

Cat with a larger percentage decrease than the median in NT-proBNP concentration from admission to discharge had a significantly longer survival time than cats with a smaller percentage decrease than the median. In people, a > 30% decrease has been found to be a significant marker, but in this study that was not found to be significant. Median survival time for cats with the larger percentage decrease in NT-proBNP concentration was 182 days, while median survival time for cats with a smaller percentage decrease was 60 days.

Take-home points

Decrease in NT-proBNP concentration can be an important prognostic factor in determining survival time for cats with congestive heart failure. A larger decrease in NT-proBNP concentration after treatment is a positive prognostic factor. Unfortunately, at this time specific levels of decrease could not be determined as definitively prognostic. However, with a larger study sample size it is likely specific guidelines can be established.

Pierce KV, Rush JE, Freeman LM, et al. Association between survival time and changes in NT-proBNP in cats treated for congestive heart failure. J Vet Intern Med 2017;31:678-684.

Link to abstract: https://www.ncbi.nlm.nih.gov/pubmed/28370373

Related Content:

CardiologyFeline Medicine
Combining the best of private practice with clinic spay/neuter care
Combining the best of private practice with clinic spay/neuter care
Constant-rate infusions for feline pain
Constant-rate infusions for feline pain
Gene therapy demonstrates benefit to dogs with myxomatous mitral valve disease
Gene therapy demonstrates benefit to dogs with myxomatous mitral valve disease

Advertisement

Latest News

Pride, representation, and inclusion in vet med

Partnership to promote diversity in veterinary medicine and more

Morris Animal Foundation accepting canine cancer research proposals

AI-enhanced MyLabX90VET ultrasound system unveiled

View More Latest News
Advertisement